Drug intelligence / Profile preview

PH-6

Development stage: Preclinical
Lead developer: Peak Bio
Modality: Small Molecules
Administration: Intravenous

Overview

PH-6 is a proprietary cytotoxic toxin platform developed by Peak Bio to serve as a payload for antibody-drug conjugates (ADCs). It is part of Peak Bio's portfolio of ADC technologies, which also includes the PH-1 splicing modulator and the PH-5 toxin platform. PH-6 is designed to be chemically linked to targeting antibodies, allowing for the selective delivery of the cytotoxic agent to malignant cells while sparing healthy tissue. While the specific molecular target of the PH-6 toxin (such as DNA or microtubules) has not been publicly disclosed, it is utilized in the company's discovery and preclinical oncology pipeline to create next-generation targeted cancer therapies.

Other names: PH-6 toxin platformPH6 toxin platformPH 6 toxin platformPH-6 payloadPH6 payloadPH 6 payload

Beyond the preview

Go deeper on PH-6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PH-6.

Explore the full profile